

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

DATE OF BOARD MEETING

The board (“**Board**”) of directors (“**Directors**”) of New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) announces that a meeting of the Board will be held on Tuesday, 29 March 2022 for the purposes of, among other matters, considering and approving the final results of the Group for the year ended 31 December 2021 and its publication thereof, and considering the payment of a final dividend, if any.

On behalf of the Board

New Ray Medicine International Holding Limited

Wang Qiuqin

Chairman & Executive Director

Hong Kong, 17 March 2022

As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong and Mr. Chu Xueping; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.

Note:

*Trading in the shares of the Company (“**Shares**”) has been suspended with effect from 9:00 a.m. on 6 October 2017 by The Stock Exchange of Hong Kong Limited as directed by the Securities and Futures Commission in accordance with its direction issued under Section 8(1) of the Securities and Futures (Stock Market Listing) Rules (Chapter 571V, the Laws of Hong Kong). Trading in the Shares will remain suspended until further notice. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.*